Dennis J. Selkoe

The paper identifies that Aβ aggregates bind the U1 snRNP in Alzheimer's disease brain, linking Aβ aggregation to spliceosome dysfunction and connecting it to other fibril-forming proteins in neurodegenerative diseases.

The paper develops and validates CNS-tau-specific monoclonal antibodies for use in neuropathology and plasma biomarker assays across Alzheimer's disease and primary tauopathies.

The paper examines somatic mutations in neurons across tau pathologic states in Alzheimer's disease and finds increased mutation burden and specific mutational signatures in AD neurons.

This study examines how different anti-amyloid antibodies bind to various Aβ aggregates in human Alzheimer's brains and how this relates to ARIA-E risk.

The paper assesses the pathogenicity of PSEN2 variants by comparing Aβ production and homology to PSEN1 variants, finding correlations with age at symptom onset.

This study identifies fibrinogen as a plasma protein binding partner for lecanemab biosimilar, suggesting it may affect drug half-life and free antibody levels in Alzheimer's disease therapy.

The paper quantifies Aβ production from PSEN1 variants and links it to clinical and biomarker progression in ADAD, showing strong associations with disease trajectories.

The paper reports the presence of abundant Aβ fibrils in aqueous extracts from Alzheimer's disease brains, with structures identical to those in amyloid plaques.

This study shows miR-132 protects neurons from tauopathy-related damage by regulating multiple pathways and reducing Tau pathology in mice.